The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). by Quartier, P. et al.
Vol.:(0123456789) 
Rheumatology International (2018) 38 (Suppl 1):S195–S201 
https://doi.org/10.1007/s00296-018-3951-2
VALIDATION STUDIES
The French version of the Juvenile Arthritis Multidimensional 
Assessment Report (JAMAR)
Pierre Quartier1 · Michael Hofer2,3 · Carine Wouters4 · Thi Thanh Thao Truong1 · Ngoc‑Phoi Duong1 · 
Kokou‑Placide Agbo‑Kpati1 · Florence Uettwiller1 · Isabelle Melki1 · Richard Mouy1 · Brigitte Bader‑Meunier1 · 
Alessandro Consolaro5,6 · Francesca Bovis5 · Nicolino Ruperto5 · For the Paediatric Rheumatology International 
Trials Organisation (PRINTO)
Received: 22 December 2017 / Accepted: 11 January 2018
© The Author(s) 2018. This article is an open access publication
Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the French lan-
guage. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre 
was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients 
seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation 
phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling 
effects, internal consistency, Cronbach’s alpha, interscale correlations and construct validity (convergent and discriminant 
validity). A total of 100 JIA patients (23% systemic, 45% oligoarticular, 20% RF negative polyarthritis, 12% other categories) 
and 122 healthy children, were enrolled at the paediatric rheumatology centre of the Necker Children’s Hospital in Paris. 
Notably, none of the enrolled JIA patients is affected with psoriatic arthritis. The JAMAR components discriminated well 
healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the 
French version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine 
clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the French parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
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We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the French language.
Materials and methods
The methodology employed has been described in detail 
in the introductory paper of the supplement [4]. In brief, 
it was a cross-sectional study of JIA children, classified 
according to the ILAR criteria [5, 6] and enrolled from 
April 2014 to June 2016. Children were recruited after 
Ethics Committee approval and consent from at least one 
parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL), PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal items-scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
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reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18]. Test–retest reliability of the French version of 
the JAMAR was not assessed.
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete French parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross cultural adaptation
The French JAMAR was fully cross-culturally adapted 
from the standard English version with three forward and 
two backward translations with a concordance for 121/123 
(98.4%) translations lines for the parent version and 118/120 
(98.3%) lines for the child version.
The text of the parent and patient JAMAR were left 
unmodified after the probe technique: as confirmed by the 
local principal investigator in charge of the validation pro-
cess, all the 10 probe parents and patients understood cor-
rectly the content of all questionnaire lines.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 122 healthy children (total of 
222 subjects), were enrolled at the paediatric rheumatology 
centre of the Necker Children’s Hospital in Paris.
In the 100 JIA subjects, the JIA categories were 23% with 
systemic arthritis, 45% with oligoarthritis, 20% with RF-
negative polyarthritis, 3% with RF-positive polyarthritis, 5% 
with enthesitis-related arthritis and 4% with undifferenti-
ated arthritis. Notably, none of the enrolled JIA patients is 
affected with psoriatic arthritis (Table 1).
A total of 212/222 (95.5%) subjects had the parent ver-
sion of the JAMAR completed by a parent (93 from parents 
of JIA patients and 119 from parents of healthy children). 
The JAMAR was completed by 169/212 (79.7%) mothers 
and 43/212 (20.3%) fathers. The child version of the JAMAR 
was completed by 97/222 (43.7%) children age 10.3 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses was 0.0% (0–1.1%). The response pattern for 
both PF and HRQoL was positively skewed toward normal 
functional ability and normal HRQoL. All response choices 
were used for the different HRQoL items except for item 8, 
whereas a reduced number of response choices were used 
for PF items 6, 7, 9, 10 and 11.
The mean and SD of the items within a scale were 
roughly equivalent for the PF (except for item 15) and for 
the HRQoL items (data not shown). The median number of 
items marked as not applicable was 0% (0–0%) for the PF 
and 1.5% (1–2%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 75.3% (73.1–82.8%) for the PF 
items, 58.1% (43–66.7%) for the HRQoL physical health 
(PhH) items, and 55.9% (54.8–61.3%) for the HRQoL psy-
chosocial health (PsH) items. The median ceiling effect was 
1.1% (0–3.2%) for the PF items, 4.3% (2.2–6.5%) for the 
HRQoL PhH items, and 2.2% (1.1–2.2%) for the HRQoL 
PsH items. The median floor effect was 36.6% for the pain 
VAS, 33.3% for the disease activity VAS and 35.5% for the 
well-being VAS. The median ceiling effect was 0.0% for the 
pain VAS, 0.0% for the disease activity VAS and 2.1% for 
the well-being VAS.
Equal items‑scale correlations (second Likert 
assumption)
Pearson items–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 100% of the 
PF items and for 100% of the HRQoL items.
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Items internal consistency (third Likert assumption)
Pearson items–scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.91 for PF-LL, 0.91 for PF-HW, 0.92 
for PF-US. Cronbach’s alpha was 0.88 for HRQoL PhH and 
0.85 for HRQoL PsH.
Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 100 JIA patients
Data related to the JAMAR refers to the 93 JIA patients and to the 119 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL Health-Related Quality of Life (total score ranges from 0 to 30), PhH Physical Health (total score ranges 
from 0 to 15), PsH Psychosocial Health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05 **p < 0.001 #p < 0.0001
Systemic Oligoarthritis RF − Polyar-
thritis
RF + Polyar-
thritis
Enthesitis-
related arthritis
Undifferentiated 
arthritis
All JIA patients Healthy
N = 23 N = 45 N = 20 N = 3 N = 5 N = 4 N = 100 N = 122
Female 10 (43.5%) 39 (86.7%) 17 (85%) 1 (33.3%) 2 (40%) 4 (100%) 73 (73%)** 65 (53.3%)*
Age at visit 11.5 (7.1–14.9) 11.6 (8.9–13.3) 11.6 (7.5–13.9) 17.2 (11.7–19) 14.5 (13–16.5) 12 (8.6–15.1) 11.7 (8.5–14) 9 (5–12.2)#
Age at onset 3.1 (2.1–8.5) 2.3 (1.5–3.6) 3.5 (1.4–6.2) 4.8 (3.1–11.7) 7 (6.4–8.8) 4.8 (3–7.3) 3.1 (1.6–5.3)*
Disease duration 5.7 (3.8–8.4) 8 (5.4–10.9) 7.9 (4.6–9.6) 7.3 (6.9–14.1) 7.6 (7.4–9.3) 6.7 (5.6–7.8) 7.5 (5.2–10)
ESR 1 (1–1) 1 (1–1) 1 (0–1) 0 (0–0) 1 (1–1) 1 (0.5–1) 1 (0–1)*
MD VAS 
(0–10 cm)
0.5 (0–1.5) 0 (0–1) 1 (0–2) 0.5 (0.5–4) 0.5 (0–1.5) 2 (1.8–2) 0.5 (0–1.5)
No. swollen joints 0 (0–0) 0 (0–0) 0 (0–1.5) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–0)
No. joints with 
pain
0 (0–1) 0 (0–0) 0.5 (0–2) 0 (0–0) 0 (0–1) 2.5 (0–5.5) 0 (0–1)
No. joints with 
LOM
1 (0–27) 0 (0–1) 3 (1.5–15.5) 3 (2–19) 0 (0–0) 0 (0–0.5) 1 (0–4.5)**
No. active joints 0 (0–0) 0 (0–1) 1 (0–2) 0 (0–1) 0 (0–1) 0 (0–0) 0 (0–1)
Active systemic 
features
1 (4.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
ANA status 2 (8.7%) 14 (31.1%) 4 (20%) 1 (33.3%) 0 (0%) 1 (25%) 22 (22%)
Uveitis 0 (0%) 25 (55.6%) 2 (10%) 0 (0%) 0 (0%) 1 (25%) 28 (28%)#
PF Total Score 1 (0–10) 0 (0–2) 5.5 (3–8) 3.5 (3–4) 3 (3–6) 3 (0.5–11.5) 1 (0–6)* 0 (0–0)#
Pain VAS 1.5 (0–2) 0.5 (0–2.5) 1.5 (0–3) 3.8 (1–6.5) 2.8 (1.3–5.8) 4.8 (2.5–6.8) 1 (0–3) 0 (0–0)#
Disease Activity 
VAS
1 (0–3) 0 (0–2) 2 (0.5–5) 3.5 (0.5–6.5) 3.5 (1–6.5) 2.8 (1.3–5.5) 1 (0–3)
Well-being VAS 2 (0–3) 0 (0–3) 2.5 (0.5–6) 3.3 (0–6.5) 1 (0.5–6.5) 3 (2–5.8) 1 (0–4)
HRQoL PhH 3 (1–6) 1 (0–4) 3 (0–4) 5 (3–7) 4 (0–6) 4 (3–7) 2 (0–5) 0 (0–0)#
HRQoL PsH 3 (1–4) 1 (0–3) 2.5 (0–6) 2.5 (0–5) 5 (4–6) 5.5 (3.5–53) 2 (0–4)* 0 (0–2)#
HRQoL Total 
Score
7 (2–9) 2 (1–5) 5.5 (3–10) 7.5 (3–12) 9 (4–16) 12 (9.5–56) 4 (1–9)* 0 (0–2)#
Pain/swell. in > 1 
joint
9/21 (42.9%) 16/43 (37.2%) 13/18 (72.2%) 1/2 (50%) 5 (100%) 4 (100%) 48/93 
(51.6%)**
4/119 (3.4%)#
Morning stiff-
ness > 15 min
5/21 (23.8%) 5/43 (11.6%) 3/18 (16.7%) 0 (0%) 0 (0%) 2 (50%) 15/93 (16.1%) 0 (0%)#
Subjective remis-
sion
10/21 (47.6%) 19/43 (44.2%) 13/18 (72.2%) 1/2 (50%) 3 (60%) 4 (100%) 50/93 (53.8%)
In treatment 20/21 (95.2%) 42/43 (97.7%) 17/18 (94.4%) 1/2 (50%) 5 (100%) 4 (100%) 89/93 (95.7%)
Reporting side 
effects
4/20 (20%) 18/40 (45%) 4/16 (25%) 1/1 (100%) 2 (40%) 2 (50%) 31/86 (36%)
Taking medica-
tion regularly
14/20 (70%) 39/41 (95.1%) 17/17 (100%) 0 (0%) 4 (80%) 4 (100%) 78/88 (88.6%)*
With problems 
attending school
6/17 (35.3%) 6/30 (20%) 4/13 (30.8%) 0 (0%) 0 (0%) 4 (100%) 20/67 (29.9%)* 0 (0%)#
Satisfied with dis-
ease outcome
20/21 (95.2%) 31/41 (75.6%) 11/18 (61.1%) 2/2 (100%) 3 (60%) 2 (50%) 69/91 (75.8%) 116 (97.5%)#
S199Rheumatology International (2018) 38 (Suppl 1):S195–S201 
1 3
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.4 to 0.7 
(median = 0.6). The PF total score best correlation was 
observed with the disease activity VAS (r = 0.7, p < 0.001). 
For the HRQoL, the median correlation of the PhH with 
the JIA core set of outcome variables ranged from 0.4 to 
0.7 (median = 0.7), whereas for the PsH ranged from 0.2 
to 0.5 (median = 0.4). The PhH showed the best correla-
tion with the disease activity VAS (r = 0.7, p < 0.001) and 
the PsH with the parent global assessment of well-being 
(r = 0.6, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity 
VAS and the physician-centred and laboratory meas-
ures were 0.4 (0.1–0.5), 0.4 (0.1–0.5), 0.5 (0.1–0.6), 
respectively.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiophatic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL Health-Related Quality of Life, PhH Physical Health, PsH Psychosocial Health, PF-LL PF-lower limbs, PF-HW PF-hand and 
wrist, PF-US PF-upper segment
Parent N = 93/212 Child N = 58/97
Missing values (1st–3rd quartiles) 0.0 (0.0–1.1) 0.0 (0.0–1.7)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 75.3% 84.5%
 HRQoL PhH 58.1% 51.7%
 HRQoL PsH 55.9% 53.4%
 Pain VAS 36.6% 34.5%
 Disease activity VAS 33.3% 36.2%
 Well-being VAS 35.5% 39.7%
Ceiling effect, median
 PF 1.1% 1.7%
 HRQoL PhH 4.3% 5.2%
 HRQoL PsH 2.2% 3.4%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 2.1% 1.7%
Items with equivalent item-scale correlation 100% for PF, 100% for HRQoL 80% for PF, 70% for HRQoL
Items with items-scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 80% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.91 0.85
 PF-HW 0.91 0.86
 PF-US 0.92 0.40
 HRQoL PhH 0.88 0.83
 HRQoL PsH 0.85 0.83
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 87% for PF, 90% for HRQoL
Spearman correlation with JIA core set variables, median
 PF 0.6 0.6
 HRQoL PhH 0.7 0.6
 HRQoL PsH 0.4 0.4
 Pain VAS 0.4 0.4
 Disease activity VAS 0.4 0.4
 Well-being VAS 0.5 0.5
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Discussion
In this study, the French version of the JAMAR was cross-
culturally adapted from the standard English version with 
three forward and two backward translations. According to 
the results of the validation analysis, the French parent and 
patient versions of the JAMAR possess satisfactory psycho-
metric properties. The disease-specific components of the 
questionnaire discriminated well between patients with JIA 
and healthy controls. This finding indicates that children 
with JIA adapt well to the consequences of JIA.
The PF total score proved to discriminate between the 
different JIA subtypes with children with RF-poly-arthri-
tis having a higher degree of disability. The HRQoL PsH 
and HRQoL total score proved to discriminate between the 
different JIA subtypes with children with undifferentiated 
arthritis having a lower quality of life.
Psychometric performances were good for all domains of 
the JAMAR and the overall internal consistency was good 
for all the domains. Test–retest reliability was not assessed 
in this patient sample.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters range from moderate to strong.
The statistical performances of the child version of the 
JAMAR are very similar, although slightly poorer, to those 
obtained by the parent version, which suggests that children 
are reliable reporters of their disease and health status.
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the French version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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